By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...
Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...
Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...
Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL).
Tomasson: Elranatamab is a bispecific antibody that binds to the BCMA on the tumor cells and the CD3-positive bone marrow ...
The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.
This whitepaper discusses the classification of bsAbs targeting immunomodulatory checkpoints and highlights their ...
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.
Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...
Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback